The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical Outcomes of patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with nab-paclitaxel + carboplatin (nab-P/C) and solvent-based paclitaxel + carboplatin (sb-P/C) stratified by age and renal function: a retrospective analysis of a phase III trial.
 
Eric Bernicker
Consulting or Advisory Role - Bristol-Myers Squibb; Clovis Oncology; Daiichi Sankyo
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Clovis Oncology; Daiichi Sankyo
 
Mark A. Socinski
Honoraria - Genentech
Consulting or Advisory Role - Genentech
Speakers' Bureau - Genentech
Research Funding - Genentech (Inst)
 
Amy Ko
Employment - Celgene
Stock and Other Ownership Interests - Celgene
 
Teng Jin Ong
Employment - Celgene
Stock and Other Ownership Interests - Celgene
 
Corey J. Langer
Honoraria - Bristol-Myers Squibb; Genentech/Roche; Lilly/ImClone
Consulting or Advisory Role - Abbott Biotherapeutics; Bayer/Onyx; Cancer Support Community; Celgene; Clarient; Clovis Oncology; Genentech/Roche; Lilly/ImClone; Merck; Millennium
Research Funding - Advantagene (Inst); Ariad (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Inovio Pharmaceuticals (Inst); Merck (Inst)